China Biotech Services Holdings Limited provided consolidated earnings guidance for the six months ended 30 June 2019. Group is expected to record a net loss of not less than HKD 33,000,000 for the 2019 Interim as compared to the net loss of approximately HKD 28,345,000 recorded for the corresponding period in 2018. The increase in net loss for the 2019 Interim was mainly attributable to (i) increase in administrative expenses due to increase in staff costs and research and development costs; and (ii) decrease in gross profit due to increase raw material, staff costs and other direct costs in medical laboratory testing and health check services.